Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?

In conclusion, appropriate composites of cefoperazone and β-lactamase inhibitor sulbactam may expand the clinical use if the pharmacokinetic optimization could be achieved in the human serum.
PMID: 33418147 [PubMed - as supplied by publisher]

Source: Infection, Genetics and Evolution - January 5, 2021 Category: Genetics & Stem Cells Authors: Ku YH, Yu WL Tags: Infect Genet Evol Source Type: research